PLIANT THERAPEUTICS, INC. — fact timeline

PLIANT THERAPEUTICS, INC. shareholders approved Ratification of appointment of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-11 meeting.

“Proposal No. 3: The Company’s stockholders ratified the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The voting results are as follows: For Against Abstain 41,710,604 747,140 69,239 There were no broker non-votes for Proposal No. 3.”

PLIANT THERAPEUTICS, INC. shareholders approved Non-binding advisory vote to approve the compensation of the Company’s named executive officers at the 2026-06-11 meeting.

“Proposal No. 2: The Company’s stockholders approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers. The voting results are as follows: For Against Abstain 15,282,788 14,572,455 776,605 The broker non-votes for Proposal No. 2 totaled 11,895,135 shares of common stock.”

PLIANT THERAPEUTICS, INC. shareholders approved Election of three Class III directors to serve until the 2029 Annual Meeting at the 2026-06-11 meeting.

“Proposal No. 1: The Company’s stockholders approved the election of each of the aforementioned Class III director nominees to serve until the 2029 Annual Meeting of Stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation, or removal. The voting results are as follows: Nominee For Withhold Bernard Coulie, M.D., Ph.D., MBA 18,824,540 11,807,308 Gayle Crowell 18,186,914 12,444,934 Steve Krognes, MBA 19,299,728 11,332,120 The broker non-votes for Proposal No. 1 totaled 11,895,135 shares of common stock.”

PLIANT THERAPEUTICS, INC. reported first quarter ended March 31, 2026 results: net income Net loss was $20.0 million.

“On May 11, 2026, Pliant Therapeutics, Inc. (the "Company") issued a press release announcing the Company’s financial results for the first quarter ended March 31, 2026.”

PLIANT THERAPEUTICS, INC. reported fourth quarter ended December 31, 2025 results: net income $23.6 million.

“Net loss was $23.6 million as compared to $49.7 million for the prior-year quarter.”

PLIANT THERAPEUTICS, INC. issued securities.

“On March 3, 2026, Pliant Therapeutics, Inc. (the “Company”) and Computershare Trust Company, N.A., as rights agent (the “Rights Agent”), entered into an Amendment to Stockholder Rights Agreement (the “Amendment”), amending the Stockholder Rights Agreement, dated as of March 12, 2025, between the Company and the Rights Agent (the “Rights Agreement”). The Amendment changes the final expiration time of the Rights (as defined in the Rights Agreement) from 5:00 p.m., New York City time on March 11, 2026 to 5:00 p.m., New York City time on March 11, 2027.”

PLIANT THERAPEUTICS, INC.: Stockholders approved an amendment to the Amended and Restated Certificate of Incorporation to limit the liability of certain officers as permitted by Delaware law, effective June 9, 2025 (effective 2025-06-09).

“At the Annual Meeting, the stockholders of the Company approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to limit the liability of certain officers of the Company, as permitted by Delaware law (the “Amendment”), as further described in the Company’s Definitive Proxy Statement filed with the U.S. Securities and Exchange Commission on April 23, 2025 (the “Proxy Statement”). The Amendment became effective upon the filing of a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware on June 9, 2025.”

PLIANT THERAPEUTICS, INC. announced a restructuring with charges of $3.6 million (approximately 45% of its current employees).

“current employees. The Company expects to substantially complete the workforce reduction by the end of the second quarter of 2025. The Company expects to recognize approximately $3.6 million in total for severance and related benefits for employees laid off under the reduction in force. These charges are primarily one-time termination benefits and are primarily cash”

Mike Ouimette was terminated as Chief Legal and Compliance Officer and Corporate Secretary at PLIANT THERAPEUTICS, INC..

“On May 1, 2025, the Company announced that in connection with the workforce reduction, the employment of Mike Ouimette, the Company’s Chief Legal and Compliance Officer and Corporate Secretary, would terminate effective May 1, 2025.”

PLIANT THERAPEUTICS, INC.: Adopted Certificate of Designation for Series A Junior Participating Preferred Stock in connection with stockholder rights agreement (effective 2025-03-13).

“In connection with the adoption of the Rights Agreement described in Item 3.03 of this Current Report, the Board approved a Certificate of Designation of Series A Junior Participating Preferred Stock, which designates the rights, preferences and privileges of 300,000 shares of a series of the Company’s preferred stock, par value $0.0001 per share, designated as Series A Junior Participating Preferred Stock.”

PLIANT THERAPEUTICS, INC. reported first quarter ended March 31, 2024 results: net income Net loss of $47.0 million.

“Pliant Therapeutics, Inc. (the "Company") issued a press release announcing the Company’s financial results for the first quarter ended March 31, 2024.”

PLIANT THERAPEUTICS, INC. incurred credit facility of $150.0 million with Oxford Finance LLC at (i) the greater of (a) 1-month term SOFR and (b) three and one-half percent (3.5 maturing March 1, 2029, which may be extended to March 1, 2030.

“pursuant to which, the Lenders have agreed to lend the Company, subject to the terms and conditions therein, a series of term loans up to an aggregate principal amount of $150.0 million (the “Term Loans”), of which $50.0 million is subject to the Lender’s sole discretion. Pursuant to the Agreement, the Company drew an initial Term Loan of $30.0 million on the”

PLIANT THERAPEUTICS, INC. amended Amended and Restated Loan and Security Agreement with Oxford Finance LLC and the lenders valued at $150.0 million (effective 2024-03-11).

“On March 11, 2024 (the “Effective Date”), Pliant Therapeutics, Inc. (the “Company”) entered into an Amended and Restated Loan and Security Agreement (“Agreement”) by and among the Company, the lenders from time to time party thereto (each a “Lender” and collectively, the “Lenders”) and Oxford Finance LLC, in its capacity as collateral agent (in such capacity, the “Agent”), which amends and restates, in its entirety, the Loan and Security Agreement, dated as of May 4, 2022”

PLIANT THERAPEUTICS, INC. reported fourth quarter ended December 31, 2023 results: net income Net loss was $41.1 million.

“Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today provided a corporate update and reported fourth quarter 2023 financial results.”

PLIANT THERAPEUTICS, INC. reported financial results for third quarter ended September 30, 2023.

“On November 9, 2023, Pliant Therapeutics, Inc. (the "Company") issued a press release announcing the Company’s financial results for the third quarter ended September 30, 2023.”

PLIANT THERAPEUTICS, INC. terminated Littlefield Lease Termination with Healthpeak OP, LLC valued at Termination 60 days after Oyster Point Lease commencement; no penalty (effective 2023-09-28).

“In connection with the entry into the Oyster Point Lease, the Company entered into a termination agreement (the “Termination Agreement”) with Healthpeak OP, LLC, a Maryland limited liability company, successor-interest to HCP, Inc. (“Healthpeak”) with respect to the Company’s lease (the “Littlefield Lease”) of 260 Littlefield Avenue, South San Francisco, California 94080 (“Littlefield Premises”).”

PLIANT THERAPEUTICS, INC. entered into Oyster Point Lease with HCP BTC, LLC valued at $0.26 million/month initial, $0.71 million/month final; 7 years; $1.43M letter of credit (effective 2023-09-28).

“On September 28, 2023, Pliant Therapeutics, Inc., a Delaware Corporation (the “Company”) entered into a lease agreement (the “Oyster Point Lease”) with HCP BTC, LLC, a Delaware limited liability company (the “Landlord”).”

PLIANT THERAPEUTICS, INC. shareholders approved Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-07 meeting.

“Proposal 3: The Company’s stockholders ratified the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm. The votes cast at the Annual Meeting were as follows: For Against Abstain 54,811,068 12,512 19,255”

PLIANT THERAPEUTICS, INC. shareholders approved Approval, by non-binding advisory vote, of the compensation of the Company’s named executive officers at the 2023-06-07 meeting.

“Proposal 2: The Company’s stockholders approved, by non-binding advisory vote, the compensation of the Company’s named executive officers, as follows: For Against Abstain 47,994,590 1,379,942 36,200 The broker non-votes for Proposal 2 totaled 5,432,103 shares of common stock.”

PLIANT THERAPEUTICS, INC. shareholders approved Election of Bernard Coulie, M.D., Ph.D., Gayle Crowell and Suzanne Bruhn, Ph.D. as Class III directors at the 2023-06-07 meeting.

“Proposal 1: The Company’s stockholders approved the election of the aforementioned Class III directors recommended for election at the Annual Meeting. The Company’s stockholders voted for the Class III directors as follows: Nominee For Withhold Bernard Coulie, M.D., Ph.D. 48,316,375 1,094,357 Gayle Crowell 39,771,872 9,638,860 Suzanne Bruhn, Ph.D. 39,735,738 9,674,994 The broker non-votes for Proposal 1 totaled 5,432,103 shares of common stock.”

PLIANT THERAPEUTICS, INC. reported the first quarter ended March 31, 2023 results: net income Net loss of $37.5 million.

“On May 9, 2023, Pliant Therapeutics, Inc. (the "Company") issued a press release announcing the Company’s financial results for the first quarter ended March 31, 2023.”

PLIANT THERAPEUTICS, INC. reported financial results for the fourth quarter ended December 31, 2022.

“On March 9, 2023, Pliant Therapeutics, Inc. (the "Company") issued a press release announcing the Company’s financial results for the fourth quarter ended December 31, 2022.”

Darren Cline was appointed as Director at PLIANT THERAPEUTICS, INC..

“the Board appointed, upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating and Governance Committee”), each of Thomas McCourt and Darren Cline to fill the Class II and Class I vacancies on the Board, respectively.”

Thomas McCourt was appointed as Director at PLIANT THERAPEUTICS, INC..

“the Board appointed, upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating and Governance Committee”), each of Thomas McCourt and Darren Cline to fill the Class II and Class I vacancies on the Board, respectively.”

PLIANT THERAPEUTICS, INC. reported preliminary financial results for the quarter and year ended December 31, 2022.

“Our financial statements for the quarter and year ended December 31, 2022 will not be available until after this offering is completed and consequently will not be available to you prior to investing in this offering. Based upon preliminary estimates and information available to us as of the date of this prospectus supplement, we expect to report that we had approximately $331.2 million of cash, cash equivalents and short-term investments as of December 31, 2022.”

Neil Exter retired as Member of the Board of Directors at PLIANT THERAPEUTICS, INC..

“On November 16, 2022, Neil Exter, MBA, a member of the Board of Directors (the “Board”) of Pliant Therapeutics, Inc. (the “Company”) since 2015, notified the Board that he would retire from the Board and as a member of the Compensation Committee of the Board, in each case effective as of November 16, 2022.”

PLIANT THERAPEUTICS, INC. reported financial results for third quarter ended September 30, 2022.

“Pliant Therapeutics, Inc. (the "Company") issued a press release announcing the Company’s financial results for the third quarter ended September 30, 2022.”

Katharine Knobil was appointed as Director at PLIANT THERAPEUTICS, INC..

“the Board of Directors (the “Board”) of Pliant Therapeutics, Inc. (the “Company”) appointed, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, Dr. Katharine Knobil to fill a newly created Board seat”